In such disorders, termed dystroglycanopathies, loss of ECM binding correlates with loss of binding to glycan-dependent α dystroglycan monoclonal antibodies such as IIH616. Here, DAG1 is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.